Demographic and characteristics of patients identified with OVT
| Characteristics . | No. of patients (%) . |
|---|---|
| Age at diagnosis, y | Average, 43.4 |
| Range, 20-87 | |
| Race | Asian n = 1 |
| Black or African American, n = 28 (56%) | |
| Other, n = 2 | |
| White, n = 19 | |
| Signs or symptoms of OVT | Incidental, n = 9 |
| Fever, n = 4 | |
| Abdominal or pelvic pain, n = 36 (72%) | |
| Unclear/not documented, n = 1 | |
| Laterality | Bilateral, n = 7 |
| Left, n = 12 | |
| Right, n = 30 (60%) | |
| Unknown, n = 1 | |
| Occlusive | No, n = 15 |
| Yes, n = 19 (38%) | |
| Unknown, n = 16 | |
| Hypercoagulable | Sickle cell trait, n = 1 |
| Anticardiolipin Ab positive, n = 1 | |
| Extension into adjacent veins or other thrombi identified simultaneously diagnosis | Extension in adjacent veins, n = 4 (into IVC, n = 3; renal veins, n = 1) |
| Other pelvic thrombi identified simultaneously, n = 2 | |
| PE identified simultaneously, n= 2 | |
| Iliac vein thrombus identified simultaneously n = 2 | |
| Symptomatic LE DVT identified simultaneously, n = 1 | |
| Context of diagnosis | Active malignancy, n = 11 |
| Peripartum or postpartum, n = 9 | |
| Recent surgery (<3 mo), n = 11 | |
| Remote surgery (>3 mo), n = 3 | |
| Hypercoagulable by history or laboratory diagnosis, n = 2 | |
| Active infection (appendicitis, pancreatitis, PID) n = 4 | |
| No apparent risk factors/provocation: incidental finding, n = 8 | |
| Unknown, n = 2 | |
| Treatment | Anticoagulation alone, n = 30 (warfarin or LMWH) |
| Anticoagulation with antibiotics, n = 3 | |
| Antiplatelet (aspirin,) n = 1 | |
| IVC filter, n = 2 | |
| None, n = 12 | |
| Unknown, n = 2 |
| Characteristics . | No. of patients (%) . |
|---|---|
| Age at diagnosis, y | Average, 43.4 |
| Range, 20-87 | |
| Race | Asian n = 1 |
| Black or African American, n = 28 (56%) | |
| Other, n = 2 | |
| White, n = 19 | |
| Signs or symptoms of OVT | Incidental, n = 9 |
| Fever, n = 4 | |
| Abdominal or pelvic pain, n = 36 (72%) | |
| Unclear/not documented, n = 1 | |
| Laterality | Bilateral, n = 7 |
| Left, n = 12 | |
| Right, n = 30 (60%) | |
| Unknown, n = 1 | |
| Occlusive | No, n = 15 |
| Yes, n = 19 (38%) | |
| Unknown, n = 16 | |
| Hypercoagulable | Sickle cell trait, n = 1 |
| Anticardiolipin Ab positive, n = 1 | |
| Extension into adjacent veins or other thrombi identified simultaneously diagnosis | Extension in adjacent veins, n = 4 (into IVC, n = 3; renal veins, n = 1) |
| Other pelvic thrombi identified simultaneously, n = 2 | |
| PE identified simultaneously, n= 2 | |
| Iliac vein thrombus identified simultaneously n = 2 | |
| Symptomatic LE DVT identified simultaneously, n = 1 | |
| Context of diagnosis | Active malignancy, n = 11 |
| Peripartum or postpartum, n = 9 | |
| Recent surgery (<3 mo), n = 11 | |
| Remote surgery (>3 mo), n = 3 | |
| Hypercoagulable by history or laboratory diagnosis, n = 2 | |
| Active infection (appendicitis, pancreatitis, PID) n = 4 | |
| No apparent risk factors/provocation: incidental finding, n = 8 | |
| Unknown, n = 2 | |
| Treatment | Anticoagulation alone, n = 30 (warfarin or LMWH) |
| Anticoagulation with antibiotics, n = 3 | |
| Antiplatelet (aspirin,) n = 1 | |
| IVC filter, n = 2 | |
| None, n = 12 | |
| Unknown, n = 2 |
LMWH, low-molecular-weight heparin; PID, pelvic inflammatory disease.